Biomaterial Database

[Fundamental and clinical studies on cefamandole in the field of obstetrics and gynecology (author's transl)]. 1980

K Hirabayashi, and E Okada

1) Tissue concentrations of cefamandole (CMD) one hour after the end of 2 g/30 approximately 60 minutes drip infusion were 7.3 approximately 13.1 microgram/g in uterus, ovary and oviduct. These concentrations were higher than MICs of 70 approximately 100% of causative organisms, including Staphylococcus aureus, Escherichia coli, Klebsiella, Proteus mirabilis, Enterobacter and Citrobacter, isolated from the infections in the field of obstetrics and gynecology. 2) CMD was administered to 14 patients with moderate infections in the field of obstetrics and gynecology at a daily dose of 4 g for 5 approximately 7 days. The overall clinical efficacy obtained was as follows; excellent in 7 cases (50%), good in 3 cases (21%) and poor in 4 cases (29%). 3) Antimicrobial activity of CMD against causative organisms resembled that of CEZ. 4) No adverse effects and abnormal laboratory findings were observed. From the above, we considered that CMD was an effective and safe antibiotic against infections in the field of obstetrics and gynecology.

UI	MeSH Term	Description	Entries
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D002435	Cefamandole	Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.	Cephamandole,Compound 83405
D002511	Cephalosporins	A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid.	Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D005260	Female		Females
D005831	Genital Diseases, Female	Pathological processes involving the female reproductive tract (GENITALIA, FEMALE).	Gynecologic Diseases,Female Genital Diseases,Diseases, Female Genital,Diseases, Gynecologic,Female Genital Disease,Genital Disease, Female,Gynecologic Disease
D005836	Genitalia, Female	The female reproductive organs. The external organs include the VULVA; BARTHOLIN'S GLANDS; and CLITORIS. The internal organs include the VAGINA; UTERUS; OVARY; and FALLOPIAN TUBES.	Accessory Sex Organs, Female,Sex Organs, Accessory, Female,Genital Organs, Female,Genitals, Female,Reproductive System, Female,Female Genital,Female Genital Organ,Female Genital Organs,Female Genitalia,Female Genitals,Female Reproductive System,Female Reproductive Systems,Genital Organ, Female,Genital, Female,Reproductive Systems, Female
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D000368	Aged	A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available.	Elderly